MURA•benzinga•
Mural Oncology Says ARTISTRY-7 Phase 3 Trial Of Nemvaleukin Alfa In Combination With Merck's Keytruda Versus Investigator's Choice Chemotherapy For Platinum-resistant Ovarian Cancer Will Not Continue To Final Analysis And The Company Will Cease Developme
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 25, 2025 by benzinga